ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Writer Cosmos Announces Exclusive Feature on Dr. Howard Covant's Debut Sci-Fi Novel

Dr. Howard Covant discusses the philosophical and scientific themes of his debut sci-fi novel, Destiny: A Future Fate of Mankind, in an exclusive interview with The New York Times.

Toronto, Canada, 12th Dec 2025 - Writer Cosmos, a leading global publishing organization, today announced a special interview with Dr. Howard Covant, veterinarian, biomedical scientist, and author, in The New York Times. The interview provides an in-depth look at the inspiration behind Destiny: A Future Fate of Mankind, Covant's debut science fiction novel that explores humanity's potential to transcend the cycles of history through scientific and philosophical lenses.

A Fusion of Science and Fiction: The Making of Destiny

Destiny: A Future Fate of Mankind is the culmination of four decades of work in biomedical sciences and philosophical reflection. Dr. Covant, who spent his career studying the relationship between science, technology, and society, draws on his expertise to craft a science fiction narrative that feels grounded in scientific plausibility. Over eight years of development, Covant integrated themes from evolutionary biology, morality, and human progress into the book, creating a futuristic world that remains scientifically sound.

"I had to make the science believable," Dr. Covant said in his interview. "Many professionals have said that the concepts in this book feel possible. That was important to me."

The novel introduces innovative technologies like the "comm-link," a wearable communication device, and PIP, an artificial intelligence companion. These concepts reflect Covant's deep understanding of emerging technologies and their potential impact on society, capturing both their promise and inherent risks.

Exploring Optimism in Science Fiction

While modern science fiction often leans toward dystopian narratives, Dr. Covant's novel represents a departure, aligning more closely with the optimistic outlook of pioneers like H.G. Wells, Jules Verne, and Gene Roddenberry. Dr. Covant views science fiction as a genre of possibility, where humanity can envision a future of progress and potential.

"For me, science fiction has always been something of promise," he remarked. "It allows us to look forward and consider the great things humanity will encounter."

This optimistic vision is particularly evident in the two contrasting societies featured in the novel: the Republican Empire, a religious theocracy, and the Corporation, a technologically advanced civilization. Through these societies, Destiny raises thought-provoking questions about humanity's moral evolution, the forces that shape history, and whether societies can break free from repeating the mistakes of the past.

Philosophical Themes: Morality, Evolution, and Free Will

At the heart of Destiny lies an exploration of humanity's capacity for moral growth and the direction of human evolution. Dr. Covant presents a narrative where the protagonist, Martin Tabir, embarks on a personal journey of transformation that mirrors the larger questions of freedom, morality, and destiny.

Tabir, a reluctant hero rather than a chosen one, struggles with his identity and role in the future of humanity. Dr. Covant designed this character to show how personal growth can reflect broader societal and spiritual development.

"He's someone whose development shows that people have strength and spirit," Dr. Covant said. "We can become more--if we choose to."

The novel also grapples with the idea that humanity is evolving toward greater benevolence and goodness, even amid the rise and fall of civilizations. Despite the challenges faced by the characters, Dr. Covant maintains an optimistic view of the future, believing that humanity is on a path toward positive change.

Early Reader Response and Future Plans

Since its release, Destiny has generated strong reactions from early readers, who praise its pacing, philosophical depth, and compelling characters. Many have found it difficult to put the book down, highlighting its ability to engage with both intellectual and emotional aspects of the reader's experience.

Dr. Covant has already begun working on a follow-up to Destiny, eager to continue exploring the scientific and philosophical questions introduced in the first novel. Fans can expect to see more from the author in the coming years as he builds on the foundations laid in Destiny.

About Dr. Howard Covant

Dr. Howard Covant is a veterinarian, biomedical scientist, and professor with over 40 years of experience in academia. His extensive background in biomedical science has provided him with a unique perspective on human compassion, scientific progress, and the integration of technology into society. Destiny: A Future Fate of Mankind is his debut novel, marking his transition from academic work to fiction.

About Writer Cosmos

Writer Cosmos is a premier global publishing and editorial services organization, dedicated to supporting authors across genres. With a focus on refining manuscripts, marketing, and literary development, Writer Cosmos offers a comprehensive suite of services for authors at all stages of their publishing journey.

For more information about Writer Cosmos and their work with authors, visit www.writercosmos.com.

Phone: +1 678-257-7555

Website: www.writercosmos.com

Media Contact

Organization: Writer Cosmos

Contact Person: Vincent Layton

Website: http://www.writercosmos.com

Email: Send Email

City: Toronto

Country:Canada

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.54
-3.65 (-1.61%)
AAPL  274.11
-4.17 (-1.50%)
AMD  207.58
-3.20 (-1.52%)
BAC  55.33
+0.19 (0.34%)
GOOG  309.32
-1.20 (-0.39%)
META  647.51
+3.28 (0.51%)
MSFT  474.82
-3.71 (-0.78%)
NVDA  176.29
+1.27 (0.73%)
ORCL  184.92
-5.05 (-2.66%)
TSLA  475.31
+16.35 (3.56%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.